| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $6.0M | 0.01% | 326.81K | +0.8% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a CGEM trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 7, 2026 | Michaelson JenniferOfficer | Sale at price 21.57 per share. | 8K | $172.56K |
| Sep 7, 2026 | Michaelson JenniferOfficer | Conversion of Exercise of derivative security at price 4.30 per share. | 4K | $17.20K |
| Aug 12, 2026 | Michaelson JenniferOfficer | Sale at price 20.26 per share. | 30K | $607.80K |
| Aug 12, 2026 | Michaelson JenniferOfficer | Conversion of Exercise of derivative security at price 4.30 per share. | 30K | $129.00K |
| Jul 5, 2026 | Michaelson JenniferOfficer | Sale at price 17.82 per share. | 8K | $142.56K |
| Jul 5, 2026 | Michaelson JenniferOfficer | Conversion of Exercise of derivative security at price 4.30 per share. | 4K | $17.20K |
| Jun 29, 2026 | Fenton Mary KayChief Financial Officer | Stock Award(Grant) at price 18.21 per share. | 1.5K | $28.06K |
| Jun 29, 2026 | Sumer Jacquelyn LOfficer | Stock Award(Grant) at price 18.21 per share. | 2.5K | $44.98K |
| May 4, 2026 | Michaelson JenniferOfficer | Sale at price 14.60 - 15.58 per share. | 8K | $117.00K |
| May 4, 2026 | Michaelson JenniferOfficer | Conversion of Exercise of derivative security at price 4.30 per share. | 4K | $17.20K |
| Mar 4, 2026 | Michaelson JenniferOfficer | Sale at price 15.68 per share. | 8K | $125.44K |
| Mar 4, 2026 | Michaelson JenniferOfficer | Conversion of Exercise of derivative security at price 4.30 per share. | 4K | $17.20K |
| Feb 24, 2026 | Michaelson JenniferOfficer | Sale at price 14.14 per share. | 1.8K | $25.17K |
| Feb 23, 2026 | Ahmed NadimChief Executive Officer | Sale at price 14.47 per share. | 13.5K | $195.56K |
| Feb 23, 2026 | Michaelson JenniferOfficer | Sale at price 13.99 - 14.47 per share. | 5.4K | $76.62K |
| Feb 23, 2026 | Sumer Jacquelyn LOfficer | Sale at price 14.47 per share. | 3.6K | $52.11K |
| Feb 23, 2026 | Jones Jeffrey AlanOfficer | Sale at price 14.47 per share. | 4.6K | $66.30K |
| Feb 19, 2026 | Fenton Mary KayChief Financial Officer | Sale at price 13.62 per share. | 4.4K | $59.90K |
| Feb 19, 2026 | Ahmed NadimChief Executive Officer | Sale at price 13.62 per share. | 16.4K | $223.11K |
| Feb 19, 2026 | Michaelson JenniferOfficer | Sale at price 13.62 - 14.30 per share. | 11.7K | $165.37K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 15.6 | 29.6 | -8.3 | -8.2 | 26.0 | 10.8 | -9.4 | 33.8 | -30.4 | -8.1 | +36.2% | ||
| 2025 | -13.3 | -19.6 | -10.8 | 9.4 | 4.4 | -12.9 | 3.2 | -3.0 | -21.4 | 46.0 | 31.3 | -9.0 | −15.0% |
| 2024 | 48.6 | 22.0 | -7.7 | 58.5 | -13.0 | -25.8 | 11.0 | 1.3 | -14.6 | -7.1 | -13.5 | -9.4 | +19.5% |
| 2023 | 10.3 | -3.0 | -9.4 | -4.9 | 5.7 | 4.7 | -1.6 | -2.3 | -12.6 | 3.1 | -12.2 | 24.4 | −3.4% |
| 2022 | -12.6 | 6.4 | -27.0 | -6.3 | 9.0 | 19.9 | 5.4 | -0.2 | -4.9 | 2.5 | -5.4 | -15.1 | −31.6% |
| 2021 | 6.3 | 3.1 | -22.1 | -8.4 | -13.4 | -11.0 | 23.1 | -20.0 | -1.6 | -19.0 | -14.3 | −59.4% |
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Buy / hold / sell counts